GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

Paula L McClean; Nigel Irwin; Roslyn S Cassidy; Jens Juul Holst; Victor A Gault; Peter R Flatt

doi:10.1152/ajpendo.00460.2007

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

Paula L McClean, Nigel Irwin, Roslyn S Cassidy, Jens Juul Holst, Victor A Gault, Peter R Flatt

Endocrinology and Metabolism

187 Citations (Scopus)

Abstract

The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP receptor antagonist, (Pro(3))GIP, in mice previously fed a high-fat diet for 160 days to induce obesity and related diabetes. Daily intraperitoneal injection of (Pro(3))GIP over 50 days significantly decreased body weight compared with saline-treated controls, with a modest increase in locomotor activity but no change of high-fat diet intake. Plasma glucose, glycated hemoglobin, and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro(3))GIP treatment also significantly decreased circulating glucagon and corticosterone, but concentrations of GLP-1, GIP, resistin, and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy, and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance, and normalization of glucose tolerance in (Pro(3))GIP-treated high-fat-fed mice. (Pro(3))GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.

Original language	English
Journal	American Journal of Physiology: Endocrinology and Metabolism
Volume	293
Issue number	6
Pages (from-to)	E1746-55
ISSN	0193-1849
DOIs	https://doi.org/10.1152/ajpendo.00460.2007
Publication status	Published - Dec 2007

Keywords

Adipokines
Adipose Tissue
Animals
Anti-Obesity Agents
Blood Glucose
Body Weight
Corticosterone
Dietary Fats
Eating
Gastric Inhibitory Polypeptide
Glucagon
Glucagon-Like Peptide 1
Glucose Intolerance
Incretins
Insulin
Insulin Resistance
Lipids
Liver
Male
Mice
Motor Activity
Muscle, Skeletal
Obesity
Pancreas
Receptors, Gastrointestinal Hormone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1152/ajpendo.00460.2007

Cite this

McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007). GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American Journal of Physiology: Endocrinology and Metabolism, 293(6), E1746-55. https://doi.org/10.1152/ajpendo.00460.2007

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. / McClean, Paula L; Irwin, Nigel; Cassidy, Roslyn S et al.

In: American Journal of Physiology: Endocrinology and Metabolism, Vol. 293, No. 6, 12.2007, p. E1746-55.

Research output: Contribution to journal › Journal article › Research › peer-review

McClean, PL, Irwin, N, Cassidy, RS, Holst, JJ, Gault, VA & Flatt, PR 2007, 'GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet', American Journal of Physiology: Endocrinology and Metabolism, vol. 293, no. 6, pp. E1746-55. https://doi.org/10.1152/ajpendo.00460.2007

@article{b8a36df24d4a444faf8bff6f90b46ef0,

title = "GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet",

abstract = "The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP receptor antagonist, (Pro(3))GIP, in mice previously fed a high-fat diet for 160 days to induce obesity and related diabetes. Daily intraperitoneal injection of (Pro(3))GIP over 50 days significantly decreased body weight compared with saline-treated controls, with a modest increase in locomotor activity but no change of high-fat diet intake. Plasma glucose, glycated hemoglobin, and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro(3))GIP treatment also significantly decreased circulating glucagon and corticosterone, but concentrations of GLP-1, GIP, resistin, and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy, and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance, and normalization of glucose tolerance in (Pro(3))GIP-treated high-fat-fed mice. (Pro(3))GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.",

keywords = "Adipokines, Adipose Tissue, Animals, Anti-Obesity Agents, Blood Glucose, Body Weight, Corticosterone, Dietary Fats, Eating, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose Intolerance, Incretins, Insulin, Insulin Resistance, Lipids, Liver, Male, Mice, Motor Activity, Muscle, Skeletal, Obesity, Pancreas, Receptors, Gastrointestinal Hormone",

author = "McClean, {Paula L} and Nigel Irwin and Cassidy, {Roslyn S} and Holst, {Jens Juul} and Gault, {Victor A} and Flatt, {Peter R}",

year = "2007",

month = dec,

doi = "10.1152/ajpendo.00460.2007",

language = "English",

volume = "293",

pages = "E1746--55",

journal = "American Journal of Physiology - Endocrinology and Metabolism",

issn = "0193-1849",

publisher = "American Physiological Society",

number = "6",

}

TY - JOUR

T1 - GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

AU - McClean, Paula L

AU - Irwin, Nigel

AU - Cassidy, Roslyn S

AU - Holst, Jens Juul

AU - Gault, Victor A

AU - Flatt, Peter R

PY - 2007/12

Y1 - 2007/12

N2 - The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP receptor antagonist, (Pro(3))GIP, in mice previously fed a high-fat diet for 160 days to induce obesity and related diabetes. Daily intraperitoneal injection of (Pro(3))GIP over 50 days significantly decreased body weight compared with saline-treated controls, with a modest increase in locomotor activity but no change of high-fat diet intake. Plasma glucose, glycated hemoglobin, and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro(3))GIP treatment also significantly decreased circulating glucagon and corticosterone, but concentrations of GLP-1, GIP, resistin, and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy, and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance, and normalization of glucose tolerance in (Pro(3))GIP-treated high-fat-fed mice. (Pro(3))GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.

AB - The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP receptor antagonist, (Pro(3))GIP, in mice previously fed a high-fat diet for 160 days to induce obesity and related diabetes. Daily intraperitoneal injection of (Pro(3))GIP over 50 days significantly decreased body weight compared with saline-treated controls, with a modest increase in locomotor activity but no change of high-fat diet intake. Plasma glucose, glycated hemoglobin, and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro(3))GIP treatment also significantly decreased circulating glucagon and corticosterone, but concentrations of GLP-1, GIP, resistin, and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy, and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance, and normalization of glucose tolerance in (Pro(3))GIP-treated high-fat-fed mice. (Pro(3))GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.

KW - Adipokines

KW - Adipose Tissue

KW - Animals

KW - Anti-Obesity Agents

KW - Blood Glucose

KW - Body Weight

KW - Corticosterone

KW - Dietary Fats

KW - Eating

KW - Gastric Inhibitory Polypeptide

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose Intolerance

KW - Incretins

KW - Insulin

KW - Insulin Resistance

KW - Lipids

KW - Liver

KW - Male

KW - Mice

KW - Motor Activity

KW - Muscle, Skeletal

KW - Obesity

KW - Pancreas

KW - Receptors, Gastrointestinal Hormone

U2 - 10.1152/ajpendo.00460.2007

DO - 10.1152/ajpendo.00460.2007

M3 - Journal article

C2 - 17848629

SN - 0193-1849

VL - 293

SP - E1746-55

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

IS - 6

ER -

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this